Categories: Top News

BeyondSpring Receives Nasdaq Delinquency Notice Regarding Late Filing of Its Form 6-K

NEW YORK, Jan. 10, 2024 (GLOBE NEWSWIRE) — BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a global clinical-stage biopharmaceutical company focused on using a groundbreaking technology platform for drug discovery and developing innovative therapies to improve clinical outcomes for patients with high unmet medical needs, today announced that on January 4, 2024, it received a Foreign Delinquency Compliance Plan Alert Letter (the “Letter”) from The Nasdaq Stock Market LLC (“Nasdaq”). In the Letter, the staff of Nasdaq notified the Company that it is not in compliance with Nasdaq Listing Rule 5250(c)(2), because it has not timely filed its Form 6-K for the period ended June 30, 2023 (the “Filing”).

In accordance with Nasdaq Listing Rules, the Company has 60 calendar days to submit a plan to regain compliance. If Nasdaq accepts the Company’s plan, Nasdaq can grant the Company an exception of up to 180 calendar days from the Filing’s due date, or until July 1, 2024, to regain compliance.

The Letter has no immediate effect on the listing or trading of the Company’s ordinary shares on Nasdaq. The Company’s management is working diligently to complete the Filing as soon as practicably possible to regain compliance with the Nasdaq Listing Rule 5250(c)(2).

About BeyondSpring
BeyondSpring (NASDAQ: BYSI) is a global clinical-stage biopharmaceutical company focused on developing innovative therapies to improve clinical outcomes for patients with high unmet medical needs. The Company is advancing its first-in-class lead asset, Plinabulin, as a direct anti-cancer agent in various cancer indications and to prevent chemotherapy-induced neutropenia. Its pipeline also includes three preclinical immuno-oncology assets. Additionally, BeyondSpring’s subsidiary, SEED Therapeutics, leverages a proprietary targeted protein degradation (TPD) drug discovery platform and has an initial R&D collaboration with Eli Lilly. Learn more by visiting https://beyondspringpharma.com.

Investor Contact:
IR@beyondspringpharma.com

Media Contact:
PR@beyondspringpharma.com

 

GlobeNewswire

GlobeNewswire, is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Recent Posts

The opinion of the Supervisory Board of Enefit Green AS on the voluntary takeover bid made by Eesti Energia AS on 8 April 2025.

Hereby we publish the opinion of the Supervisory Board of Enefit Green AS on the…

4 hours ago

Bitcoin ‘breaking out’ as it retakes $87K after early April slump

Bitcoin is now more correlated with gold, which reached another all-time high, while the US…

15 hours ago

Bitcoin price surging on Sunday evening

If BTC can break through the resistance level of $86,000, it may target higher levels,…

15 hours ago

ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Zynex, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – ZYXI

NEW YORK, April 20, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights…

19 hours ago

Writer/painter-turned cultural heritage preserver behind Spring Festival’s UNESCO heritage status success

Global Times: Feng Jicai leads efforts to preserve China's cultural heritage through art, literature, and…

20 hours ago

Boston Hemp Launches New Line of Premium THCa Concentrates

Hanover, MA , April 20, 2025 (GLOBE NEWSWIRE) -- Boston Hemp Inc., a leader in…

20 hours ago

This website uses cookies.